{"id":"v7","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"V7 is a therapeutic HIV vaccine candidate developed by Immunitor LLC that aims to boost cellular and humoral immune responses against HIV. The vaccine is intended to be used as an adjunctive therapy in HIV-infected patients to enhance immune control of the virus and potentially reduce viral load.","oneSentence":"V7 is an immunotherapeutic vaccine designed to stimulate the immune system against HIV infection.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:54:04.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV infection (therapeutic vaccine in treatment-experienced patients)"}]},"trialDetails":[{"nctId":"NCT07219277","phase":"","title":"Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening","status":"RECRUITING","sponsor":"Syantra Inc.","startDate":"2026-01-07","conditions":"Breast Cancer, Liquid Biopsy, Early Detection","enrollment":2000},{"nctId":"NCT07399327","phase":"NA","title":"Biomarkers of Response to SEEG Thermocoagulation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2026-03-01","conditions":"Drug Resistant Epilepsy","enrollment":45},{"nctId":"NCT06411353","phase":"NA","title":"Blood Flow Conditions and Sounds in AVFs","status":"RECRUITING","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2025-03-01","conditions":"End Stage Renal Disease","enrollment":15},{"nctId":"NCT05322343","phase":"","title":"Biobank and Brain Health in Bordeaux.","status":"RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2022-03-22","conditions":"Brain, Aging, Cognitive Aging","enrollment":2050},{"nctId":"NCT05759078","phase":"PHASE4","title":"Effect of INtravenous FERRic Carboxymaltose Onmortality and Cardiovascular Morbidity, and Quality of Life in Iron Deficient Patients With Recent Myocardial infarCTion","status":"RECRUITING","sponsor":"Wroclaw Medical University","startDate":"2022-09-22","conditions":"Myocardial Infarction, Acute","enrollment":1000},{"nctId":"NCT00812669","phase":"PHASE2","title":"CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7","status":"COMPLETED","sponsor":"Cancer Trials Ireland","startDate":"2008-08-18","conditions":"Leukemia","enrollment":52},{"nctId":"NCT03627403","phase":"PHASE2","title":"Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors","status":"TERMINATED","sponsor":"University of Utah","startDate":"2019-05-10","conditions":"Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis","enrollment":17},{"nctId":"NCT03361735","phase":"PHASE2","title":"Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-08-29","conditions":"Prostate Adenocarcinoma","enrollment":25},{"nctId":"NCT06863987","phase":"PHASE3","title":"A Phase III Clinical Study of Valsartan Oral Solution for the Treatment of Hypertension in Children and Adolescents","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong New Time Pharmaceutical Co., LTD","startDate":"2025-02-05","conditions":"Essential Hypertension","enrollment":342},{"nctId":"NCT03002220","phase":"PHASE2","title":"Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status","status":"COMPLETED","sponsor":"MedSIR","startDate":"2016-12-21","conditions":"Prostate Cancer","enrollment":52},{"nctId":"NCT04245436","phase":"PHASE4","title":"Acute and Long-Term Antidepressant Treatment Success in Adolescents With Anxiety (AtLAS-A)","status":"RECRUITING","sponsor":"University of Cincinnati","startDate":"2020-01-01","conditions":"Anxiety, Depressive Symptoms","enrollment":60},{"nctId":"NCT03355066","phase":"PHASE1","title":"A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Biosplice Therapeutics, Inc.","startDate":"2017-11-06","conditions":"Solid Tumor, Adult","enrollment":82},{"nctId":"NCT04518410","phase":"PHASE2, PHASE3","title":"ACTIV-2: A Study for Outpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-19","conditions":"Coronavirus, Covid19","enrollment":4044},{"nctId":"NCT06279962","phase":"NA","title":"Survey Experiment to Estimate Level of Mental Illness Stigma Based on Condition and Gender","status":"COMPLETED","sponsor":"Yale University","startDate":"2023-06-15","conditions":"Mental Illness, Stigma, Social","enrollment":379},{"nctId":"NCT06380894","phase":"NA","title":"Virtual Reality Cognitive Training for Mild Cognitive Impairment","status":"COMPLETED","sponsor":"Changi General Hospital","startDate":"2021-01-27","conditions":"Mild Cognitive Impairment","enrollment":20},{"nctId":"NCT04010825","phase":"NA","title":"Impact of Hypnosis Intervention on the Emotional Dimension of Dyspnea in Patients With COPD.","status":"COMPLETED","sponsor":"5 Santé","startDate":"2019-10-25","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":106},{"nctId":"NCT06142552","phase":"PHASE3","title":"Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein","status":"RECRUITING","sponsor":"Jiangsu Gensciences lnc.","startDate":"2023-12-27","conditions":"Severe Hemophilia A","enrollment":120},{"nctId":"NCT05422560","phase":"NA","title":"Preoperative Embolization of the Inferior Mesenteric Artery in Colorectal Surgery","status":"UNKNOWN","sponsor":"University Hospital, Grenoble","startDate":"2022-09-06","conditions":"Embolism Mesenteric","enrollment":30},{"nctId":"NCT06017882","phase":"","title":"Combined Effects of Acute Sleep Restriction and Moderate Acceleration (+Gz) on Physiological and Behavioral Responses to High Mental Workload","status":"UNKNOWN","sponsor":"Direction Centrale du Service de Santé des Armées","startDate":"2023-09-11","conditions":"Sleep Deprivation","enrollment":28},{"nctId":"NCT04832321","phase":"NA","title":"Measuring Beliefs and Norms About Persons With Alcohol Use Disorder","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2021-02-19","conditions":"Alcohol Use Disorder (AUD)","enrollment":1363},{"nctId":"NCT05928754","phase":"NA","title":"Prospective CoHoRt Of Non-infectious Intermediate, pOsterior or panuveitiS","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2023-09","conditions":"Non-infectious Uveitis","enrollment":2000},{"nctId":"NCT04433052","phase":"NA","title":"Clinical Value and Cost-effectiveness of a Personalized Prevention Program (PPP) in Patients With High Risk Stable CHD","status":"RECRUITING","sponsor":"Tampere University","startDate":"2023-02-01","conditions":"Coronary Heart Disease","enrollment":12000},{"nctId":"NCT02438007","phase":"PHASE3","title":"A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC","status":"TERMINATED","sponsor":"LTN PHARMACEUTICALS, INC.","startDate":"2015-06","conditions":"Prostate Cancer","enrollment":953},{"nctId":"NCT04713670","phase":"PHASE4","title":"Comparison of Vonoprazan-based Versus Lansoprazole-based Triple Therapy, High Dose Dual Therapy, Bismuth and Non-bismuth Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-03-10","conditions":"H. Pylori Infection","enrollment":1200},{"nctId":"NCT05625581","phase":"","title":"Tofatib Treatment for IgG4-related Disease","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2022-11-10","conditions":"IgG4-related Disease","enrollment":40},{"nctId":"NCT05109559","phase":"PHASE1, PHASE2","title":"Ad26.COV2.S as a Heterologous Booster in Adults After Single- or Two-Dose of Inactivated COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2021-12-20","conditions":"SARS-CoV-2 Infection","enrollment":690},{"nctId":"NCT02601014","phase":"PHASE2","title":"Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-03-15","conditions":"Prostate Cancer, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma","enrollment":32},{"nctId":"NCT03050866","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2017-02-21","conditions":"Circulating Tumor Cell, Metastatic Prostate Cancer","enrollment":140},{"nctId":"NCT02853097","phase":"","title":"Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2016-06-14","conditions":"Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":7},{"nctId":"NCT02721043","phase":"PHASE1","title":"Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies","status":"COMPLETED","sponsor":"Nina Bhardwaj","startDate":"2016-04","conditions":"Solid Tumors","enrollment":13},{"nctId":"NCT04188275","phase":"","title":"CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION","status":"UNKNOWN","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-12-01","conditions":"D011471, D064129, D035683","enrollment":46},{"nctId":"NCT03656770","phase":"NA","title":"Measuring Beliefs and Norms About Persons With Mental Illness","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2016-12-13","conditions":"Mental Illness, Schizophrenia, Bipolar Disorder","enrollment":1782},{"nctId":"NCT01977768","phase":"PHASE3","title":"TB Immunotherapy Trial With Heat-killed M. Vaccae","status":"COMPLETED","sponsor":"Immunitor LLC","startDate":"2014-03","conditions":"Tuberculosis","enrollment":152},{"nctId":"NCT02269982","phase":"","title":"Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY","status":"COMPLETED","sponsor":"Duke University","startDate":"2015-05-14","conditions":"Prostate Cancer","enrollment":120},{"nctId":"NCT02788799","phase":"","title":"Finding LCX AMI With Posterior ECG LeadS","status":"UNKNOWN","sponsor":"Rigshospitalet, Denmark","startDate":"2017-02-01","conditions":"Myocardial Infarction","enrollment":1200},{"nctId":"NCT03102216","phase":"NA","title":"Early Point-Of-Care Blood Tests, ECG & X-rays in the Emergency Department","status":"COMPLETED","sponsor":"Helen Joseph Hospital","startDate":"2017-02-13","conditions":"Emergency Medicine, Point-of-Care Testing","enrollment":1134},{"nctId":"NCT03011138","phase":"","title":"The Relationship Between Gait Velocity and Gait Parameters","status":"COMPLETED","sponsor":"Guangzhou General Hospital of Guangzhou Military Command","startDate":"2017-01-01","conditions":"Gait Velocity","enrollment":30},{"nctId":"NCT02621190","phase":"PHASE2","title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs","status":"WITHDRAWN","sponsor":"Erasmus Medical Center","startDate":"2016-02","conditions":"Prostatic Neoplasms","enrollment":""},{"nctId":"NCT00589914","phase":"PHASE3","title":"Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","startDate":"2007-03","conditions":"Schizophrenia","enrollment":1221},{"nctId":"NCT01380119","phase":"PHASE2","title":"Tuberculosis (TB) Immunotherapy Phase 2 Study","status":"COMPLETED","sponsor":"Lisichansk Regional Tuberculosis Dispensary","startDate":"2011-08","conditions":"Tuberculosis","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2063,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["V7 or tableted heat-inactivated mycobacterium vaccae"],"phase":"phase_3","status":"active","brandName":"V7","genericName":"V7","companyName":"Immunitor LLC","companyId":"immunitor-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V7 is an immunotherapeutic vaccine designed to stimulate the immune system against HIV infection. Used for HIV infection (therapeutic vaccine in treatment-experienced patients).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}